Evidence map›Paper›PMID 24204327›Full record

ArticlePLoS genetics2013

Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans.

Paul J Norman, Jill A Hollenbach, Neda Nemat-Gorgani, Lisbeth A Guethlein, Hugo G Hilton, Marcelo J Pando, Kwadwo A Koram, Eleanor M Riley, Laurent Abi-Rached, Peter Parham

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 131 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Following Transplantation for Acute Myelogenous Leukemia, DonorJournal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. High-Resolution Characterization ofFrontiers in immunology · 2021
    Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Paul J NormanDepartments of Structural Biology and Microbiology & Immunology, Stanford University School of Medicine, Stanford, California, United States of America.
Jill A Hollenbach
Neda Nemat-Gorgani
Lisbeth A Guethlein
Hugo G Hilton
Marcelo J Pando
Kwadwo A Koram
Eleanor M Riley
Laurent Abi-Rached
Peter Parham
Stanford University · USAix-Marseille Université · FRLondon School of Hygiene & Tropical Medicine · GBNoguchi Memorial Institute for Medical Research · GH

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
STRUCTURAL BIOLOGY OF HLA-A,B ANTIGENSR01AI017892 · NIAID · STANFORD UNIVERSITY · PI PARHAM, PETER R · 1985 to 2019
$6.1M
STRUCTURAL BIOLOGY OF HLA-A/B ANTIGENSR37AI017892 · NIAID · STANFORD UNIVERSITY · PI PARHAM, PETER R · 1989 to 1998
–
NCI NIH HHS P01 CA111412NIAID NIH HHS AI17892NIAID NIH HHS R01 AI017892Wellcome TrustWellcome Trust 040328
6 · The paper itself

Abstract

Interactions between HLA class I molecules and killer-cell immunoglobulin-like receptors (KIR) control natural killer cell (NK) functions in immunity and reproduction. Encoded by genes on different chromosomes, these polymorphic ligands and receptors correlate highly with disease resistance and susceptibility. Although studied at low-resolution in many populations, high-resolution analysis of combinatorial diversity of HLA class I and KIR is limited to Asian and Amerindian populations with low genetic diversity. At the other end of the spectrum is the West African population investigated here: we studied 235 individuals, including 104 mother-child pairs, from the Ga-Adangbe of Ghana. This population has a rich diversity of 175 KIR variants forming 208 KIR haplotypes, and 81 HLA-A, -B and -C variants forming 190 HLA class I haplotypes. Each individual we studied has a unique compound genotype of HLA class I and KIR, forming 1-14 functional ligand-receptor interactions. Maintaining this exceptionally high polymorphism is balancing selection. The centromeric region of the KIR locus, encoding HLA-C receptors, is highly diverse whereas the telomeric region encoding Bw4-specific KIR3DL1, lacks diversity in Africans. Present in the Ga-Adangbe are high frequencies of Bw4-bearing HLA-B*53:01 and Bw4-lacking HLA-B*35:01, which otherwise are identical. Balancing selection at key residues maintains numerous HLA-B allotypes having and lacking Bw4, and also those of stronger and weaker interaction with LILRB1, a KIR-related receptor. Correspondingly, there is a balance at key residues of KIR3DL1 that modulate its level of cell-surface expression. Thus, capacity to interact with NK cells synergizes with peptide binding diversity to drive HLA-B allele frequency distribution. These features of KIR and HLA are consistent with ongoing co-evolution and selection imposed by a pathogen endemic to West Africa. Because of the prevalence of malaria in the Ga-Adangbe and previous associations of cerebral malaria with HLA-B*53:01 and KIR, Plasmodium falciparum is a candidate pathogen.

Indexed as

Killer Cells, NaturalSelection, GeneticAfrica South of the SaharaBlack PeopleChildEvolution, MolecularGenetics, PopulationHaplotypesHLA AntigensHumansLigandsMalariaMolecular Sequence DataReceptors, KIRHLA AntigensLigandsReceptors, KIR

Identifiers

PMID24204327
PMCPMC3814319
OpenAlexW2087034459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.